These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32848438)

  • 21. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
    Gao L; Zhao FL; Li SC
    Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China.
    Hou X; Wan X; Wu B
    Front Pharmacol; 2019; 10():480. PubMed ID: 31143117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
    Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P
    J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
    Tunis SL; Minshall ME; Conner C; McCormick JI; Kapor J; Yale JF; Groleau D
    Curr Med Res Opin; 2009 May; 25(5):1273-84. PubMed ID: 19366302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China.
    Cui M; Tu CC; Chen EZ; Wang XL; Tan SC; Chen C
    Adv Ther; 2016 Sep; 33(9):1600-11. PubMed ID: 27397588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Effectiveness of Primary Prevention with Statin Treatment for Chinese Patients with Type 2 Diabetes.
    Li T; Wan X; Ma J; Wu B
    Adv Ther; 2018 Dec; 35(12):2214-2223. PubMed ID: 30390239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strategies to Screen for Diabetic Retinopathy in Chinese Patients with Newly Diagnosed Type 2 Diabetes: A Cost-Effectiveness Analysis.
    Wu B; Li J; Wu H
    Medicine (Baltimore); 2015 Nov; 94(45):e1989. PubMed ID: 26559285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China.
    Gao T; Liu J; Wu J
    Int J Environ Res Public Health; 2021 Jun; 18(12):. PubMed ID: 34201096
    [No Abstract]   [Full Text] [Related]  

  • 31. Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China.
    Salem A; Men P; Ramos M; Zhang YJ; Ustyugova A; Lamotte M
    J Comp Eff Res; 2021 Apr; 10(6):469-480. PubMed ID: 33576249
    [No Abstract]   [Full Text] [Related]  

  • 32. Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK.
    Ramos M; Cummings MH; Ustyugova A; Raza SI; de Silva SU; Lamotte M
    Diabetes Ther; 2020 Sep; 11(9):2041-2055. PubMed ID: 32700188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis.
    Zeng X; Liu Q; Tan C; Wan X; Wang Y; Ma X
    Front Pharmacol; 2022; 13():1003483. PubMed ID: 36339555
    [No Abstract]   [Full Text] [Related]  

  • 34. Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure.
    Alkhatib N; Sweitzer NK; Lee CS; Erstad B; Slack M; Gharaibeh M; Karnes J; Klimecki W; Ramos K; Abraham I
    Am J Cardiovasc Drugs; 2021 Mar; 21(2):205-217. PubMed ID: 32710439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic evaluation of olmesartan/amlodipine fixed-dose combination for hypertension treatment in China.
    Ren M; Xuan D; Lu Y; Fu Y; Xuan J
    J Med Econ; 2020 Apr; 23(4):394-400. PubMed ID: 31782677
    [No Abstract]   [Full Text] [Related]  

  • 36. Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.
    Gu S; Deng J; Shi L; Mu Y; Dong H
    J Med Econ; 2015; 18(10):808-20. PubMed ID: 25950193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
    Ericsson Å; Pollock RF; Hunt B; Valentine WJ
    J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.